AU2013358944B2 - DNA antibody constructs and method of using same - Google Patents

DNA antibody constructs and method of using same Download PDF

Info

Publication number
AU2013358944B2
AU2013358944B2 AU2013358944A AU2013358944A AU2013358944B2 AU 2013358944 B2 AU2013358944 B2 AU 2013358944B2 AU 2013358944 A AU2013358944 A AU 2013358944A AU 2013358944 A AU2013358944 A AU 2013358944A AU 2013358944 B2 AU2013358944 B2 AU 2013358944B2
Authority
AU
Australia
Prior art keywords
acid sequence
nucleic acid
recombinant nucleic
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013358944A
Other languages
English (en)
Other versions
AU2013358944A1 (en
Inventor
Seleeke FLINGAI
Karupiah MUTHUMANI
Niranjan Sardesai
David B. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Original Assignee
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Inovio Pharmaceuticals Inc filed Critical University of Pennsylvania Penn
Publication of AU2013358944A1 publication Critical patent/AU2013358944A1/en
Application granted granted Critical
Publication of AU2013358944B2 publication Critical patent/AU2013358944B2/en
Priority to AU2016259451A priority Critical patent/AU2016259451A1/en
Priority to AU2019202343A priority patent/AU2019202343B2/en
Priority to AU2021203643A priority patent/AU2021203643A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013358944A 2012-12-13 2013-12-13 DNA antibody constructs and method of using same Active AU2013358944B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2016259451A AU2016259451A1 (en) 2012-12-13 2016-11-18 DNA antibody constructs and method of using same
AU2019202343A AU2019202343B2 (en) 2012-12-13 2019-04-04 DNA antibody constructs and method of using same
AU2021203643A AU2021203643A1 (en) 2012-12-13 2021-06-03 DNA antibody constructs and method of using same

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261737094P 2012-12-13 2012-12-13
US61/737,094 2012-12-13
US201361881376P 2013-09-23 2013-09-23
US61/881,376 2013-09-23
US201361896646P 2013-10-28 2013-10-28
US61/896,646 2013-10-28
PCT/US2013/075137 WO2014093894A2 (en) 2012-12-13 2013-12-13 Dna antibody constructs and method of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016259451A Division AU2016259451A1 (en) 2012-12-13 2016-11-18 DNA antibody constructs and method of using same

Publications (2)

Publication Number Publication Date
AU2013358944A1 AU2013358944A1 (en) 2015-05-28
AU2013358944B2 true AU2013358944B2 (en) 2016-08-18

Family

ID=50935092

Family Applications (7)

Application Number Title Priority Date Filing Date
AU2013358944A Active AU2013358944B2 (en) 2012-12-13 2013-12-13 DNA antibody constructs and method of using same
AU2014361811A Active AU2014361811B2 (en) 2012-12-13 2014-12-13 DNA antibody constructs and method of using same
AU2016259451A Abandoned AU2016259451A1 (en) 2012-12-13 2016-11-18 DNA antibody constructs and method of using same
AU2018202997A Abandoned AU2018202997A1 (en) 2012-12-13 2018-04-30 DNA antibody constructs and method of using same
AU2019202343A Active AU2019202343B2 (en) 2012-12-13 2019-04-04 DNA antibody constructs and method of using same
AU2020201853A Active AU2020201853B2 (en) 2012-12-13 2020-03-13 DNA antibody constructs and method of using same
AU2021203643A Abandoned AU2021203643A1 (en) 2012-12-13 2021-06-03 DNA antibody constructs and method of using same

Family Applications After (6)

Application Number Title Priority Date Filing Date
AU2014361811A Active AU2014361811B2 (en) 2012-12-13 2014-12-13 DNA antibody constructs and method of using same
AU2016259451A Abandoned AU2016259451A1 (en) 2012-12-13 2016-11-18 DNA antibody constructs and method of using same
AU2018202997A Abandoned AU2018202997A1 (en) 2012-12-13 2018-04-30 DNA antibody constructs and method of using same
AU2019202343A Active AU2019202343B2 (en) 2012-12-13 2019-04-04 DNA antibody constructs and method of using same
AU2020201853A Active AU2020201853B2 (en) 2012-12-13 2020-03-13 DNA antibody constructs and method of using same
AU2021203643A Abandoned AU2021203643A1 (en) 2012-12-13 2021-06-03 DNA antibody constructs and method of using same

Country Status (15)

Country Link
US (4) US9994629B2 (enExample)
EP (1) EP2931318A4 (enExample)
JP (6) JP6898060B2 (enExample)
KR (4) KR20150093834A (enExample)
CN (1) CN104853782A (enExample)
AU (7) AU2013358944B2 (enExample)
BR (2) BR112015013700A8 (enExample)
CA (1) CA2889723A1 (enExample)
EA (1) EA201591131A1 (enExample)
HK (1) HK1213481A1 (enExample)
MX (4) MX2015007575A (enExample)
MY (1) MY175708A (enExample)
SG (1) SG10202002718RA (enExample)
WO (1) WO2014093894A2 (enExample)
ZA (1) ZA201503583B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2931318A4 (en) 2012-12-13 2016-07-20 Univ Pennsylvania DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF
US10087240B2 (en) 2013-12-13 2018-10-02 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same
KR20230145241A (ko) * 2014-10-01 2023-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
CA2969214A1 (en) * 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
EP3365366B1 (en) 2015-10-25 2021-07-14 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
US20180363000A1 (en) * 2015-12-14 2018-12-20 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
CN109890407A (zh) * 2016-03-21 2019-06-14 大卫·B·韦纳 Dna抗体构建体和其使用方法
FI3443006T3 (fi) 2016-04-13 2023-10-23 Sanofi Sa Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
KR102375327B1 (ko) * 2016-05-05 2022-03-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 관문 분자를 표적으로 하는 dna 단클론성 항체
SG10202011021XA (en) * 2016-05-05 2020-12-30 Univ Pennsylvania Dna monoclonal antibodies targeting influenza virus
SG10202011023YA (en) * 2016-05-05 2020-12-30 Univ Pennsylvania Dna monoclonal antibodies targeting il-6 and cd126
EA201892525A1 (ru) 2016-05-05 2019-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Конструкции днк-антител для применения против pseudomonas aeruginosa
CN110234346B (zh) * 2016-09-19 2024-06-04 宾夕法尼亚大学理事会 新的对抗寨卡病毒的疫苗和用于对抗寨卡病毒的dna抗体构建体的组合
TWI778985B (zh) 2016-10-20 2022-10-01 法商賽諾菲公司 抗chikv抗體及其用途
KR20230111264A (ko) * 2016-11-07 2023-07-25 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
EP3606552A4 (en) * 2017-04-07 2020-08-05 The Rockefeller University COMPOSITIONS AND METHODS RELATING TO HUMAN NEUTRALIZING ANTIBODIES DIRECTED AGAINST ZIKA VIRUS AND DENGUE VIRUS 1
TWI673285B (zh) * 2017-05-22 2019-10-01 國立成功大學 抗－登革熱病毒抗體、包含該抗體之藥學組合物及其用途
WO2019067671A1 (en) * 2017-09-27 2019-04-04 David Weiner DNA ANTIBODY CONSTRUCTS FOR USE IN CORONAVIRUS RESPIRATORY SYNDROME OF THE MIDDLE EAST
WO2019152602A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Structurally modified flavivirus dmabs
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
AU2020323601A1 (en) * 2019-07-31 2022-03-03 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
TW202124722A (zh) 2019-09-18 2021-07-01 美商英特佳樂帝克醫療公司 合成dna載體及其使用方法
SE544000C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein
SE544001C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody
WO2021188906A1 (en) * 2020-03-19 2021-09-23 Nature's Toolbox, Inc. Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same
KR20230011335A (ko) * 2020-05-14 2023-01-20 이노비오 파마수티컬즈, 인크. 재발성 호흡기 유두종증에 대한 백신 및 이의 사용 방법
EP4255484A4 (en) * 2020-12-02 2025-02-26 Thomas Jefferson University DESMOGLEIN-2-TARGETED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND METHODS OF USE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282264A1 (en) * 2009-09-25 2012-11-08 The Gov of the USA as Represented by the Secretary Dept.of Health and Human Services&University of W Neutralizing antibodies to hiv-1 and their use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI46572C (fi) * 1972-04-07 1973-04-10 Stroemberg Oy Ab Jännitemuuntaja.
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CN1334343A (zh) * 2000-07-14 2002-02-06 中国医学科学院肿瘤医院肿瘤研究所 抑制肿瘤生长的新抗体、其衍生物及其应用
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AU2003253447A1 (en) * 2002-08-02 2004-02-23 Yuhan Corporation Expression vectors
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
CN1480215A (zh) 2003-07-07 2004-03-10 叶新新 Sars病毒抗原抗体复合疫苗及实验动物模型与方法
CN102344493B (zh) * 2004-05-28 2014-09-03 艾更斯司股份有限公司 结合于psca蛋白的用于癌症诊断的抗体
MXPA06013834A (es) 2004-05-28 2007-03-01 Agensys Inc Anticuerpos y moleculas relacionadas que enlazan a proteinas psca.
EP1765846A4 (en) 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
SI1771482T1 (sl) 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2598454C (en) 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US20060216722A1 (en) 2005-03-25 2006-09-28 Christer Betsholtz Glomerular expression profiling
CA2615983A1 (en) 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
JP2009171880A (ja) 2008-01-23 2009-08-06 Yokohama City Univ アルツハイマー病における次世代遺伝子治療法・免疫治療法の開発
BRPI0909044B8 (pt) * 2008-03-14 2021-05-25 Transgene Sa anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
CN107083391A (zh) 2008-04-04 2017-08-22 宾夕法尼亚大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
US9073981B2 (en) 2008-10-13 2015-07-07 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and use thereof
JP5758888B2 (ja) 2009-07-06 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性ジゴキシゲニン結合抗体
US9598676B2 (en) 2009-07-13 2017-03-21 Bharat Biotech International Limited Composition useful as rotavirus vaccine and a method therefor
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
ES2826883T3 (es) * 2009-10-14 2021-05-19 Janssen Biotech Inc Métodos de maduración por afinidad de anticuerpos
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2012003995A1 (en) * 2010-07-09 2012-01-12 Cormus Srl Lipid-conjugated antibodies
CA3062786C (en) 2010-07-09 2022-04-19 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
KR101939150B1 (ko) 2010-11-12 2019-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
CN107090463A (zh) * 2011-01-31 2017-08-25 宾夕法尼亚大学托管会 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
WO2012115980A1 (en) * 2011-02-22 2012-08-30 California Institute Of Technology Delivery of proteins using adeno-associated virus (aav) vectors
CN102199218A (zh) * 2011-04-29 2011-09-28 中国人民解放军军事医学科学院基础医学研究所 一种抗Her2抗体-白细胞介素2融合蛋白及其用途
US9540657B2 (en) 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
EP2931318A4 (en) 2012-12-13 2016-07-20 Univ Pennsylvania DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF
JP7078350B2 (ja) * 2013-10-28 2022-05-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物及びその使用方法
AU2013358947B2 (en) 2012-12-13 2016-10-20 Inovio Pharmaceuticals, Inc. WT1 vaccine
US20140377269A1 (en) 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
US10087240B2 (en) 2013-12-13 2018-10-02 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282264A1 (en) * 2009-09-25 2012-11-08 The Gov of the USA as Represented by the Secretary Dept.of Health and Human Services&University of W Neutralizing antibodies to hiv-1 and their use

Also Published As

Publication number Publication date
AU2013358944A1 (en) 2015-05-28
MX388911B (es) 2025-03-20
AU2021203643A1 (en) 2021-07-01
KR20160093724A (ko) 2016-08-08
BR112016013493A2 (en) 2018-03-27
JP2021087433A (ja) 2021-06-10
KR102454610B1 (ko) 2022-10-13
AU2020201853A1 (en) 2020-04-02
AU2018202997A1 (en) 2018-05-17
JP2020108381A (ja) 2020-07-16
EA201591131A1 (ru) 2015-12-30
ZA201503583B (en) 2019-12-18
KR20230156146A (ko) 2023-11-13
HK1213481A1 (zh) 2016-07-08
US20220112273A1 (en) 2022-04-14
AU2020201853B2 (en) 2022-07-28
JP2023138998A (ja) 2023-10-03
US11208470B2 (en) 2021-12-28
US20180346554A1 (en) 2018-12-06
EP2931318A2 (en) 2015-10-21
MX2021015971A (es) 2022-02-10
AU2019202343B2 (en) 2021-07-01
JP2023080085A (ja) 2023-06-08
BR112015013700A8 (pt) 2020-02-18
US9994629B2 (en) 2018-06-12
AU2014361811B2 (en) 2018-02-01
WO2014093894A3 (en) 2014-07-31
SG10202002718RA (en) 2020-05-28
JP6898060B2 (ja) 2021-07-07
AU2016259451A1 (en) 2016-12-08
JP2019115355A (ja) 2019-07-18
AU2019202343A1 (en) 2019-05-02
JP2016501535A (ja) 2016-01-21
BR112016013493B1 (pt) 2024-02-27
CN104853782A (zh) 2015-08-19
KR20210088741A (ko) 2021-07-14
WO2014093894A2 (en) 2014-06-19
MX2022016002A (es) 2023-02-02
MX2015007575A (es) 2016-03-15
BR112015013700A2 (pt) 2017-11-14
KR20150093834A (ko) 2015-08-18
MX2016007722A (es) 2017-03-08
US20190085058A1 (en) 2019-03-21
US20150284448A1 (en) 2015-10-08
AU2014361811A1 (en) 2016-07-21
EP2931318A4 (en) 2016-07-20
MY175708A (en) 2020-07-06
CA2889723A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
AU2019202343B2 (en) DNA antibody constructs and method of using same
US20230023093A1 (en) Dna antibody constructs and method of using same
US10087240B2 (en) DNA antibody constructs and method of using same
JP2017500030A (ja) Ｄｎａ抗体構築物及びその使用方法
EA042816B1 (ru) Днк-конструкции антитела и способ их применения

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)